LONDON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces its participation in three upcoming conferences in November.
Truist Securities BioPharma Symposium
Panel: Considerations for an Oncology Company’s Autoimmune Side Hustle
Date and time: 9 November 2023, 11:40am ET / 16:40pm GMT
Location: New York, USA
Presenter: Dr Christian Itin, Chief Executive Officer, Autolus Therapeutics
Jefferies London Healthcare Conference
Fireside Chat
Date and time: 16 November 2023, 4:00am ET / 9:00am GMT
Location: London, UK
Presenter: Dr Christian Itin, Chief Executive Officer, Autolus Therapeutics
Piper Sandler 35th Annual Healthcare Conference
Fireside Chat
Date and time: 28 November 2023, 11:30am ET/ 16:30pm GMT
Location: New York, USA
Presenter: Dr Christian Itin, Chief Executive Officer, Autolus Therapeutics
Find out more information about upcoming events and any webcast and replay details at: https://www.autolus.com/investor-relations/events/
About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.
Contact:
Julia Wilson
+44 (0) 7818 430877
This email address is being protected from spambots. You need JavaScript enabled to view it.
Susan A. Noonan
S.A. Noonan Communications
+1-917-513-5303
This email address is being protected from spambots. You need JavaScript enabled to view it.
Lauren Williams
Investase
+44 23 9438 7760
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$2.29 |
Daily Change: | -0.20 -7.99 |
Daily Volume: | 2,227,842 |
Market Cap: | US$609.680M |
December 09, 2024 December 02, 2024 November 12, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB